journal article·2019-11Open access

Collaborative membrane activity and receptor-dependent tumor cell targeting for precise nanoparticle delivery in CXCR4+ colorectal cancer

Rita Sala, Laura Sánchez-García, Naroa Serna, María Virtudes Céspedes, Isolda Casanova, Mònica Roldán, Alejandro Sánchez-Chardi, Ugutz Unzueta, Esther Vázquez, Ramón Mangues, Antonio Villaverde

Acta Biomaterialia· Volume 99

Abstract

By the appropriate selection of functional peptides and proper accommodation sites, we have generated a set of multifunctional proteins that combine selectivity for CXCR4+ cell binding and relevant endosomal escape capabilities linked to the viral peptide HA2. In particular, the construct T22-GFP-HA2-H6 forms nanoparticles that upon administration in mouse models of human, CXCR4+ colorectal cancer, accumulates in primary tumor at levels significantly higher than the parental T22-GFP-H6 HA2-lacking version. The in vivo application of a CXCR4 antagonist has confirmed the prevalence of the CXCR4+ tumor tissue selectivity over unspecific cell penetration, upon systemic administration of the material. Such specificity is combined with improved endosomal escape, what overall results in a precise and highly efficient tumor biodistribution. These data strongly support the functional recruitment as a convenient approach to generate protein materials for clinical applications. More precisely, they also support the unexpected concept that enhancing the unspecific membrane activity of a protein material does not necessarily compromise, but it can even improve, the selective cell targeting offered by an accompanying functional module. STATEMENT OF SIGNIFICANCE: We have shown here that the combination of cell-penetrating and tumor cell-targeting peptides dramatically enhances precise tumor accumulation of protein-only nanoparticles intended for selective drug delivery, in mouse models of human colorectal cancer. This fact is a step forward for the rational design of multifunctional protein nanomaterials for improved cancer therapies.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Immunotherapy and Immune Responses · Monoclonal and Polyclonal Antibodies Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (49)

Show source-provided references
1. Functional recruitment for drug delivery through protein-based nanotechnologies10.2217/nnm-2016-0090 ↗
2. Self-assembled proteins and peptides as scaffolds for tissue regeneration10.1002/adhm.201500402 ↗
3. Recombinant structural proteins and their use in future materials
4. Design and construction of self-assembling supramolecular protein complexes using artificial and fusion proteins as nanoscale building blocks10.1016/j.copbio.2017.01.001 ↗
5. Geometric principles for designing highly symmetric self-assembling protein nanomaterials10.1146/annurev-biophys-070816-033928 ↗
6. Biomedical and catalytic opportunities of virus-like particles in nanotechnology10.1016/bs.aivir.2016.09.002 ↗
7. Rational design of new materials using recombinant structural proteins: current state and future challenges10.1016/j.jsb.2017.10.012 ↗
8. Bacterial inclusion bodies are industrially exploitable amyloids10.1093/femsre/fuy038 ↗
9. Multifunctional materials through modular protein engineering10.1002/adma.201200051 ↗
10. Supramolecular biomaterials10.1038/nmat4474 ↗
11. Nanomedicine(s) under the microscope10.1021/mp200394t ↗
12. Cancer nanomedicine: Is targeting our target?
13. Nanoparticle-delivered chemotherapy: old drugs in new packages
14. Vascular-homing peptides for cancer therapy10.1016/j.biopha.2017.05.054 ↗
15. Peptide ligand-modified nanomedicines for targeting cells at the tumor microenvironment10.1016/j.addr.2017.05.006 ↗
16. Novel advances in targeted drug delivery10.1080/1061186X.2017.1401076 ↗
17. M. Alavi, M. Hamidi, Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles. Drug metabolism and personalized therapy. 2019.10.1515/dmpt-2018-0032 ↗
18. Targeting stem cells in the realm of drug-resistant breast cancer
19. Endosomal escape pathways for delivery of biologicals10.1016/j.jconrel.2010.11.004 ↗
20. Endosomal escape: a bottleneck in intracellular delivery10.1166/jnn.2014.9082 ↗
21. Bottom-up instructive quality control in the biofabrication of smart protein materials10.1002/adma.201503676 ↗
22. CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients10.1186/1741-7015-10-85 ↗
23. Potential of CXCR4/CXCL12 chemokine axis in cancer drug delivery10.1007/s40495-015-0044-8 ↗
24. Conformational conversion during controlled oligomerization into nonamylogenic protein nanoparticles10.1021/acs.biomac.8b00924 ↗
25. Assembly of histidine-rich protein materials controlled through divalent cations10.1016/j.actbio.2018.10.030 ↗
26. Selective depletion of metastatic stem cells as therapy for human colorectal cancer10.15252/emmm.201708772 ↗
27. Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: toward a synthetic virus-like gene-transfer vehicle10.1073/pnas.89.17.7934 ↗
28. Influenza fusion peptides10.1042/bst0290623 ↗
29. Fusion of a short HA2-derived peptide sequence to cell-penetrating peptides improves cytosolic uptake, but enhances cytotoxic activity10.3390/ph2020049 ↗
30. Novel cationic antimicrobial peptide GW-H1 induced caspase-dependent apoptosis of hepatocellular carcinoma cell lines10.1016/j.peptides.2012.05.011 ↗
31. Bio-inspired design and potential biomedical applications of a novel class of high-affinity peptides10.1002/anie.201107894 ↗
32. Enhancing endosomal escape for intracellular delivery of macromolecular biologic therapeutics10.1038/srep32301 ↗
33. The fusogenic peptide HA2 impairs selectivity of CXCR4-targeted protein nanoparticles10.1039/C6CC09900A ↗
34. Recruiting potent membrane penetrability in tumor cell-targeted protein-only nanoparticles10.1088/1361-6528/aaf959 ↗
35. In vivo architectonic stability of fully de novo designed protein-only nanoparticles10.1021/nn4055732 ↗
36. A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models
37. Self-assembling toxin-based nanoparticles as self-delivered antitumoral drugs10.1016/j.jconrel.2018.01.031 ↗
38. Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12), Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection10.1016/S0968-0896(98)00061-3 ↗
39. Intracellular CXCR4+ cell targeting with T22-empowered protein-only nanoparticles
40. New insights into “permeability” as in the enhanced permeability and retention effect of cancer nanotherapeutics10.1021/acsnano.7b07214 ↗
41. Employment of enhanced permeability and retention effect (EPR): nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer10.1016/j.msec.2019.01.066 ↗
42. Fusogenic potential of prokaryotic membrane lipids. Implication in vaccine development10.1046/j.0014-2956.2001.02507.x ↗
43. Inhibitory effect of CXC chemokine receptor 4 antagonist AMD3100 on bleomycin induced murine pulmonary fibrosis10.3858/emm.2010.42.6.048 ↗
44. AMD3100 sensitizes acute lymphoblastic leukemia cells to chemotherapy in vivo10.1038/bcj.2011.13 ↗
45. AMD3100 improves ovariectomy-induced osteoporosis in mice by facilitating mobilization of hematopoietic stem/progenitor cells10.5483/BMBRep.2014.47.8.159 ↗
46. New AMD3100 derivatives for CXCR4 chemokine receptor targeted molecular imaging studies: synthesis, anti-HIV-1 evaluation and binding affinities10.1039/C4DT02972K ↗
47. Antitumor effect of CXCR4 antagonist AMD3100 on the tumorigenic cell line of BHP10-3 papillary thyroid cancer cells10.1002/hed.24461 ↗
48. Targeted intracellular delivery of therapeutics: an overview10.31083/ph.2007.9.7072 ↗
49. The enhanced green fluorescent protein as a tool for the analysis of protein dynamics and localization: local fluorescence study at the single-molecule level10.1562/0031-8655(2000)0710771TEGFPA2.0.CO2 ↗